

T: 0131-244-2528 E: irene.fazakerley@gov.scot

#### IMMEDIATE MESSAGE TO:

- 1. Directors of Pharmacy
- 2. Medical Directors NHS Boards

25 July 2024

Dear Healthcare Professional,

#### DRUG ALERT CLASS 4 DRUG ALERT 32 2024 – CLASS 4 MEDICINES DEFECT INFORMATION CAUTION IN USE – ASPEN PHARMA TRADING LTD – CO-TRIMOXAZOLE 80MG/400MG PER 5ML ADULT SUSPENSION

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

#### IRENE FAZAKERLEY Medicines Policy Team





## MEDICINES NOTIFICATION

CLASS 4 MEDICINES DEFECT INFORMATION

#### Caution in Use Pharmacy / Wholesaler Level

Date: 25 July 2024

EL (24)A/32

Our Ref: MDR 063-03/24

Dear Healthcare Professional,

### Aspen Pharma Trading Limited

#### Co-trimoxazole 80mg/400mg per 5ml adult suspension

PL 39699/0038

#### **SNOMED Code** 32280411000001100

| Batch No | Expiry Date                     | Pack Size | First Distributed |
|----------|---------------------------------|-----------|-------------------|
| B18324E  | 31 <sup>st</sup> May 2028       | 100ml     | July 2024         |
| B99324E  | 31 <sup>st</sup> May 2028       | 100ml     | July 2024         |
| B05924E  | 31 <sup>st</sup> May 2028       | 100ml     | July 2024         |
| B98724E  | 31 <sup>st</sup> May 2028       | 100ml     | July 2024         |
| B95224A  | 31 <sup>st</sup> January 2028   | 100ml     | April 2024        |
| B95324A  | 31 <sup>st</sup> January 2028   | 100ml     | April 2024        |
| B22823GA | 31 <sup>st</sup> July 2027      | 100ml     | September 2023    |
| B85623F  | 30 <sup>th</sup> June 2027      | 100ml     | July 2023         |
| B01923C  | 31 <sup>st</sup> March 2027     | 100ml     | May 2023          |
| B55023B  | 28 <sup>th</sup> February 2027  | 100ml     | March 2023        |
| B55323B  | 28 <sup>th</sup> February 2027  | 100ml     | March 2023        |
| B97222L  | 31 <sup>st</sup> December 2026  | 100ml     | January 2023      |
| B27922I  | 30 <sup>th</sup> September 2026 | 100ml     | November 2022     |
| B60922G  | 31 <sup>st</sup> July 2026      | 100ml     | August 2022       |
| B02122E  | 31 <sup>st</sup> May 2026       | 100ml     | June 2022         |
| B71922D  | 30 <sup>th</sup> April 2026     | 100ml     | May 2022          |
| B40821K  | 30 <sup>th</sup> November 2025  | 100ml     | February 2022     |
| B82321F  | 30 <sup>th</sup> June 2025      | 100ml     | July 2021         |
| B77321F  | 30 <sup>th</sup> June 2025      | 100ml     | July 2021         |
| B21921D  | 30 <sup>th</sup> April 2025     | 100ml     | May 2021          |
| B96420I  | 30 <sup>th</sup> September 2024 | 100ml     | November 2020     |
| B71220H  | 31 <sup>st</sup> August 2024    | 100ml     | September 2020    |

Active Pharmaceutical Ingredient: sulfamethoxazole, trimethoprim

#### Brief description of the problem

Aspen Pharma Trading Limited has informed the MHRA that an error has been found in the Patient Information Leaflet.

The error is in the section, 'What co-trimoxazole looks like and contents of the pack'. The PIL states '4001mg sulfamethoxazole' instead of '400 mg sulfamethoxazole'. The other sections of the PIL and product information state the correct strength.

#### Advice for healthcare professionals

Please continue to use the product as normal but be aware of the typographical error highlighted above.

# Medicines & Healthcare products Regulatory Agency

#### Advice for patients

No further action is required by patients. Patients should continue to receive this medicine from these batches as given to you by your healthcare professional. There is no impact to product quality. If you have concerns about a medicine you may be using, please contact your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the <u>MHRA Yellow Card</u> <u>scheme</u>.

#### **Further Information**

For medical information enquiries please contact: <u>Aspenmedinfo@professionalinformation.co.uk</u>, Tel: 0800 008 7392

Yours faithfully

Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574 DMRC@mhra.gov.uk